Dr. Guoqiang Zhang (China)
Chief Urology Surgeon

Dr. Zhang earned his medical degree at Shanghai Second Medical University and did further studies in Europe.

Dr. Zhang specializes in urology and extracorporeal shock wave lithotripsy treatment for lithiasis in urinary system. He diagnoses and treats complicated diseases in Urology and Andrology; male diseases such as chronic non-bacterial prostatitis (CPPS), benign prostatic hyperplasia (BPH), malignant transformation of prostate (PC), sexual dysfunction, ureteral calculi, kidney stones, urinary tract tumors, occult genitals and other diseases.

He applies different surgical techniques in treating complications, and operations such as adrenal tumor resection, radical nephrectomy, total cystectomy, orthotopic Ileal neobladder, radical prostatectomy, pyeloureteral junction surgery, ureteropelvic junction obstruction surgery, transurethral resection of the prostate (TURP), transurethral resection of bladder tumors (TURBT), ureteroscopy, holmium laser lithotripsy and other endourological procedures.

Dr. Zhang is a member of many organizations such as the Urology Committee and Male Disease Committee of Shanghai Medical Association, Medical Branch of Shanghai European and American Alumni Association, and a specialist consultant of Shanghai Male Disease Expert Medical Consultation Service Center. He was a foreign resident doctor at the Necker University Hospital in Paris and earned the certificate of foreign resident attending physician (Assistant étranger).

Dr. Zhang speaks Mandarin, French, and English.

Dr. Li graduated from the Medical School of Shanghai Jiaotong University, and further studied in Germany. He specializes in early diagnosis, surgical and non-surgical treatment for urolithiasis, prostatic hyperplasia, prostate diseases, surgery for renal and adrenal tumors, and microsurgical treatment of male diseases.

Dr. Li has won the Award of Excellent Teaching of Tongji University and second prize of Chinese Young Urologist Technical Ability and Skills Competition.

Dr. Li speaks Mandarin, English, and German.

Dr Wang has been focusing on early diagnosis, minimally invasive treatment of prostate tumors. He further studied in Japan, Germany, Hong Kong SAR and other places.

He has achieved unique research success in prostate targeted puncture, minimally invasive radical prostatectomy with nerve sparing, minimally invasive treatment of prostate tumors under the guidance of molecular imaging, precise local treatment of prostate tumors using advanced energy platform, comprehensive treatment of prostate cancer, and ultra-micro invasive treatment of prostate hyperplasia using advanced energy platform.

Dr Wang presided over 6 national key special sub projects, National Natural Science Youth Fund, Shanghai innovation action plan, Shanghai Municipal Health and Family Planning Commission fund and college fund. As the first author or corresponding author, he published over 20 SCI papers including JAMA Surgery.

In July 2022, online in JAMA surgery (if16.681, Division 1 of the literature and information center of Chinese Academy of Sciences), Dr Wang, as the first author, published Extended Focal Ablation of Localized Prostate Cancer With High-Frequency Irreversible Electroporation A Nonrandomized Controlled Trial.

For localized prostate cancer (PCA), although radiotherapy and radical prostatectomy can achieve tumor clearance, they are often accompanied by urinary incontinence, sexual dysfunction and other complications. Local treatment of PCA with high-intensity focused ultrasound, freezing, laser and photodynamic energy platforms can protect urination and erectile function, but it is difficult to achieve the optimal solution between tumor control and prostate function protection due to their technical limitations. As a new energy platform, high-frequency irreversible electroporation (h-fire) can destroy tumor cells without generating heat energy, and can selectively protect the nerve and vascular structures around the prostate. In animal experiments, it has shown better ablation effect and lower incidence of muscle spasm than the first generation irreversible electroporation (IRE), but there is no further clinical evidence.

Dr Wang cooperated with other professors teams to carry out the world's first multicenter clinical study of h-fire local treatment of prostate cancer. One arm objective behavior criteria (OPC) was used as an evaluation tool. 117 patients from May 2018 to March 2019 were selected, of whom 109 received h-fire ablation (average age 67 years). The results showed that the extensive local ablation with h-fire for PCA had good tumor control and small functional damage. The incidence of clinically significant prostate cancer (csPCA) was significantly lower than that of the previous control group with other energy platforms after a follow-up of 6 months, and the impact on prostate functions was less. The study also identified some key parameters for full ablation of h-fire.

Dr Wang's academic achievements have been widely recognized in the urology field. He actively participates in social activities. He is a member of the Urology Branch of the Chinese Medical Association and a member of the Andrology Branch of the Shanghai Medical Association.

Dr. Wang speaks Mandarin and English.

Dr Wang has been working in clinical and scientific research in urology for over 20 years. He has vast clinical experience and research achievements in the fields of urological stones, tumors, prostate diseases, etc. He is particularly skilled in minimally invasive treatment of urinary tract stones, including visualized tubeless percutaneous nephroscopy, electronic ureteroscopy, and integrated soft and hard ureteroscopy.

Dr Wang has visited and studied in Europe and Japan, e.g. the World Society of Urology (WCE), Osaka City Medical College in Japan, the International Society of Urology (SIU), and the European Society of Urology (EAU).

Dr Wang is a member of the Calculus Group of the Urology Branch of the Shanghai Medical Association, and a member of the Minimally Invasive Group of the Urology and Andrology Branch of the Shanghai Society of Integrated Chinese and Western Medicine.

Dr Wang has published over 30 scientific research articles, including SCI papers.

Dr Wang speaks Mandarin, English and Japanese.